Menu
Not yet recruiting NCT07216040

Harnessing Optimism and Perseverance in the Face of Long COVID-Español

No phase Interventional Post-Acute COVID-19 Syndrome

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: HOPE-LC~Espanol.
Who it may be relevant to
Registry conditions: Post-Acute COVID-19 Syndrome. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Harnessing Optimism and Perseverance in the Face of Long COVID~Español (HOPE-LC~Español)

Overview

The Harnessing Optimism and Perseverance in the Face of Long COVID (HOPE-LC) program, created by Drs. Eric Watson and Amelia Hicks, is a group therapy model designed to foster resilience, adjustment, and coping skills for those living with chronic Long COVID. HOPE-LC\~Español provides a culturally and linguistically adapted version for Spanish-speaking individuals in Queens, developed with input from Spanish-speaking clinicians, Long COVID experts, and people with lived experience. Partnering with H+H/Elmhurst and H+H/Queens, the project aims to recruit 25 participants and evaluate program feasibility and preliminary efficacy.

Detailed description

The Harnessing Optimism and Perseverance in the Face of Long COVID (HOPE-LC) program, developed by Drs. Eric Watson (PI) and Amelia Hicks (co-I), is a 12-week online group therapy program tailored specifically to living with Long COVID as a chronic condition. HOPE-LC provides community and hope; fostering resilience, adjustment, and critical coping strategies in the face of this debilitating chronic condition. Since its inception in 2024, the HOPE-LC groups have engaged 20 patients, emphasizing the need for chronic Long COVID therapeutic interventions.

Through HOPE-LC-Espanol the researchers will translate and adapt the HOPE-LC program into Spanish and expand HOPE-LC's reach to underserved Spanish-speaking communities in Queens and NYC. The aims are: (1) To translate and culturally adapt the HOPE-LC program for Spanish-speaking patients in collaboration with the Advisory Board of Spanish-speaking clinicians, Long COVID experts, and individuals with Long COVID lived experience; (2) In collaboration with the partners at H+H/Elmhurst and H+H/Queens, to conduct targeted recruitment to ensure the researchers are engaging specifically with local Hispanic/Latinx communities in Queens; and (3) To complete the HOPE-LC\~Español program for 25 Spanish-speaking individuals experiencing Long COVID within the local Queens community. The researchers will evaluate program feasibility and treatment success to inform future scalability and sustainability as a clinical program.

Interventions

  • Behavioral HOPE-LC~Espanol
    12-week online group therapy program grounded in principles of Acceptance and Commitment Therapy and tailored specifically to living with Long COVID as a chronic condition. HOPE-LC provides community and hope; fostering resilience, adjustment, and critical coping strategies in the face of this debilitating chronic condition.

Primary outcome measures

  • Recruitment rate [Time frame: Throughout the study period, 12 weeks]
  • Retention rate [Time frame: Throughout the study period, 12 weeks]
  • Number of sessions participants attended [Time frame: Throughout the study period, 12 weeks]
  • Number of completed surveys [Time frame: Throughout the study period, 12 weeks]
  • Patient Satisfaction [Time frame: Post-treatment (Week 12)]
Secondary outcome measures (6)
  • DePaul Symptom Questionnaire [Time frame: Baseline; 6 weeks, 12 weeks]
  • Brief Illness Perception Questionnaire (BIPQ) [Time frame: Baseline; 6 weeks, 12 weeks]
  • Valued Based Living Questionnaire (VLQ) [Time frame: Baseline; 6 weeks, 12 weeks]
  • Modified COVID-19 Yorkshire Rehabilitation Scale (C19-YRSm) [Time frame: Baseline; 6 weeks, 12 weeks]
  • Patient Health Questionnaire-8 Item (PHQ-8) [Time frame: Baseline; 6 weeks, 12 weeks]
  • Generalized Anxiety Disorder-7 Item (GAD-7) [Time frame: Baseline; 6 weeks, 12 weeks]

Eligibility criteria

Inclusion criteria

  • Age 18 years or older.
  • Speaks and understands Spanish at a level that allows active participation in group-based study procedures.
  • Self-reported history of Long COVID/post-COVID condition of any severity or duration, including ongoing emotional or cognitive symptoms affecting daily functioning or a medical professional has diagnosed you with a Long COVID/post-COVID condition of any severity or duration, including ongoing emotional or cognitive symptoms.
  • Ability to participate in group sessions either in-person or via telehealth (Zoom).
  • Willingness and capacity to provide informed consent.

Exclusion criteria

  • Presence of severe psychiatric conditions that would preclude participation in group therapy (e.g., active psychosis, suicidal intent requiring immediate intervention).
  • Inability to communicate in Spanish sufficiently to engage meaningfully in group sessions.
  • Cognitive or physical impairments prevent participation in group sessions or completion of surveys, without available accommodations.
  • Concurrent participation in another conflicting interventional trial targeting Long COVID symptoms.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

United States · 1 center
  • Brain Injury Research Center — New York

Identifiers

NCT: NCT07216040 · STUDY-25-01010

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗